CONQUEST Intervention Arm for Chronic Obstructive Pulmonary Disease

University of Colorado, Denver, CO
Chronic Obstructive Pulmonary DiseaseCONQUEST Quality Improvement Program - Other
Eligibility
18+
All Sexes

Study Summary

This trial will test whether a quality improvement and clinical decision support package can improve outcomes for patients with modifiable high-risk chronic obstructive pulmonary disease.

Eligible Conditions
  • Chronic Obstructive Pulmonary Disease (COPD)

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
N/A

Similar Trials

1
LAIV
2
Astegolimab SC Q2W
1
Ensifentrine

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: During implementation and outcome evaluation period, 2.5 years

Year 5
Exploratory Objective 1: The rate of explanatory diagnoses other than COPD
Exploratory Objective 2: Lung function
Exploratory Objective 3: Health status
Year 2
Systemic corticosteroid use (SCS)
During the 2-year outcome evaluation period
1a: COPD Exacerbations and 1b) major cardiac or respiratory events

Trial Safety

Phase-Based Safety

1 of 3

Similar Trials

1
LAIV
3
Astegolimab SC Q2W
2
Ensifentrine

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

CONQUEST Intervention Arm
1 of 1

Experimental Treatment

126 Total Participants · 1 Treatment Group

Primary Treatment: CONQUEST Intervention Arm · No Placebo Group · N/A

CONQUEST Intervention Arm
Other
Experimental Group · 1 Intervention: CONQUEST Quality Improvement Program · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: during implementation and outcome evaluation period, 2.5 years

Who is running the clinical trial?

Observational and Pragmatic Research InstituteLead Sponsor
Optimum Patient Care Global LimitedUNKNOWN
The DARTNet Institute (DI)UNKNOWN
AstraZenecaIndustry Sponsor
4,057 Previous Clinical Trials
240,391,128 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
In the PREVAIL study, the participants are primary care teams who work together to provide care for a group of patients.
You must agree to be randomly assigned to either start the CONQUEST program right away or receive usual care until the program becomes available to you later.
The doctors and patients in the study must not be able to influence each other's treatment decisions because the doctors are not blinded to the treatment being given.
The clinical trial needs a certain number of patients who meet specific high-risk criteria to be able to proceed.
References

Frequently Asked Questions

Is enrollment ongoing for this experiment?

"The clinical trial is actively recruiting, as indicated on the data posted in clinicaltrials.gov. This medical study was initially published on September 23rd 2022 and its most recent iteration went live on the 26th of that same month." - Anonymous Online Contributor

Unverified Answer

What is the current number of participants involved in this research endeavor?

"Affirmative. The data available on clinicaltrials.gov specifies that this trial, first posted September 23rd 2022, is actively recruiting patients. A total of 126 participants are needed from one medical facility." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top